Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santen Pharmaceutical Co., Ltd.

https://www.santen.com/en/

Latest From Santen Pharmaceutical Co., Ltd.

Healios, Athersys Confident Despite Missed Japan Stroke Endpoint

A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies. 

Japan Clinical Trials

Gut-Brain Connect: metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment

metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia explained their plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.

Digital Health India

Gut-Brain Connect: How metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment

metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia discuss with Scrip plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.

Commercial Digital Health

Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite

The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.

Japan Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Eyevance Pharmaceuticals LLC.
    • Novagali Pharma SA
    • Santen Inc.
    • Chongqing Santen Kerui Pharmaceutical Co., Ltd
    • InnFocus Inc,
UsernamePublicRestriction

Register